Related Experiment Video
Updated: Jan 2, 2026
09:40
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
Published on: April 11, 2016
21.6K
PPARγ and RhoBTB1 in hypertension
1Department of Pharmacology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa Department of Physiology, Cardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Current Opinion in Nephrology and Hypertension
|December 3, 2019
Summary
Peroxisome proliferator activated receptor γ (PPARγ) protects the vasculature by regulating endothelial and smooth muscle cells. Novel PPARγ targets like RBP7 and RhoBTB1 offer potential for new hypertension therapies.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Pharmacology
Background:
- Peroxisome proliferator activated receptor γ (PPARγ) is a nuclear receptor with known roles in metabolism and inflammation.
- Its specific cardioprotective mechanisms within the vasculature, particularly its transcriptional targets, require further elucidation.
Purpose of the Study:
- To review the current understanding of PPARγ's cardioprotective effects in the vasculature.
- To identify novel PPARγ target genes in endothelial and vascular smooth muscle cells mediating these effects.
Main Methods:
- Literature review of studies investigating PPARγ in cardiovascular contexts.
- Analysis of gene expression and functional studies related to PPARγ targets in vascular cells.
Main Results:
- In endothelial cells, PPARγ enhances nitric oxide bioavailability and reduces oxidative stress, with RBP7 identified as a potential feedback regulator.
- In vascular smooth muscle cells, PPARγ antagonizes the renin-angiotensin system, preserves vascular integrity, and promotes vasodilation via novel targets like RhoBTB1, which regulates phosphodiesterase 5 activity.
Conclusions:
- PPARγ exerts vascular protection through transcriptional regulation in both endothelial and smooth muscle cells.
- Understanding these novel PPARγ targets may lead to the development of new therapeutic strategies for hypertension.
Related Concept Videos
01:17Antihypertensive Drugs: Action of β1 Blockers
1.8K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.8K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.3K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.3K
01:17Hormonal Regulation of Blood Pressure
5.7K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
5.7K
01:29Hypertension II: Pathophysiology
676
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
676
01:18Hypertension and Regulation of Blood Pressure
3.6K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.6K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K